RENEE DESROSIERS: Open Payments
NPI 1922088988 · NEWPORT, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,377 in 40 payments from 16 companies in 2025. Trend: 2023 $2,079 · 2024 $1,484 · 2025 $1,377
Food & beverage: $1,278Education: $99
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 9 | $392 |
| Novo Nordisk Inc | 5 | $225 |
| MAYNE PHARMA COMMERCIAL LLC | 6 | $188 |
| Biogen, Inc. | 1 | $115 |
| Lilly USA, LLC | 4 | $89 |
| ABBVIE INC. | 3 | $82 |
| Exeltis, USA Inc. | 1 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Sage Therapeutics, LLC | 2 | $39 |
| Janssen Biotech, Inc. | 1 | $37 |
Products named: Veozah, ZURZUVAE, Wegovy, UBRELVY, ZEPBOUND, SLYND, GEMTESA, MOUNJARO.
Industry payments across RI — which companies pay providers there.
